TCGA-58-A46K-01A-11R-A24H-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 59
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.460
- G2M_CHECKPOINT+0.450
- MYC_TARGETS_V1+0.440
- MYC_TARGETS_V2+0.420
- MTORC1_SIGNALING+0.410
- UNFOLDED_PROTEIN_RESPONSE+0.400
- OXIDATIVE_PHOSPHORYLATION+0.340
- MITOTIC_SPINDLE+0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.280
- DNA_REPAIR+0.230
Top 10 suppressed
- COAGULATION-0.460
- IL6_JAK_STAT3_SIGNALING-0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- KRAS_SIGNALING_UP-0.420
- COMPLEMENT-0.400
- INFLAMMATORY_RESPONSE-0.390
- ALLOGRAFT_REJECTION-0.380
- TNFA_SIGNALING_VIA_NFKB-0.380
- ANGIOGENESIS-0.370
- PANCREAS_BETA_CELLS-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-03882 | — | cohortSQ2 | 0.901 |
| 2 | TCGA-70-6723-01A-11R-1820-07 | — | cohortSQ2 | 0.895 |
| 3 | TCGA-A8-A092-01A-11R-A00Z-07 | — | B | 0.890 |
| 4 | TCGA-85-8070-01A-11R-2247-07 | — | cohortSQ2 | 0.888 |
| 5 | TCGA-4Z-AA80-01A-11R-A39I-07 | — | — | 0.888 |
| 6 | BS_H4NXBD2D | Supratentorial Ependymoma | — | 0.880 |
| 7 | TCGA-51-4080-01A-01R-1100-07 | — | cohortSQ2 | 0.874 |
| 8 | f354d13d-89ec-4ed6-821d-df3ab230fc91 | — | — | 0.873 |
| 9 | TCGA-33-AASJ-01A-11R-A405-07 | — | cohortSQ2 | 0.870 |
| 10 | TCGA-DK-A3X2-01A-11R-A22U-07 | — | — | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.460 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.420 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.340 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.280 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.220 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.090 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.060 | Idelalisib | — uncovered |
| PEROXISOME | 0.050 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |